# An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

> **NCT03521895** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1000 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT03521895
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03521895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03521895, "An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03521895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*